{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:29Z","timestamp":1791646469473,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012579","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000}}],"reference-count":78,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012579.pub2","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T21:12:05Z","timestamp":1522185125000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral versus inhaled antibiotics for bronchiectasis"],"prefix":"10.1002","volume":"2018","author":[{"given":"Sally","family":"Spencer","sequence":"first","affiliation":[{"name":"Edge Hill University; Postgraduate Medical Institute; St Helens Road Ormskirk Lancashire UK L39 4QP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert M","family":"Felix","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS); Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Milan","sequence":"additional","affiliation":[{"name":"Lancaster University; Medical School; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Normansell","sequence":"additional","affiliation":[{"name":"St George's, University of London; Cochrane Airways, Population Health Research Institute; London UK SW17 0RE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter C","family":"Goeminne","sequence":"additional","affiliation":[{"name":"AZ Nikolaas; Sint-Niklaas Belgium"},{"name":"UZ Leuven; Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Chalmers","sequence":"additional","affiliation":[{"name":"University of Dundee, Ninewells Hospital and Medical School; Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Donovan","sequence":"additional","affiliation":[{"name":"University of Cumbria; Medical and Sport Sciences; Lancaster UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"10.1002\/14651858.CD012579.pub2-BIB0001|cit1","first-page":"A1768","article-title":"Baseline demographic profile of subjects of the phase 3 RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)","volume":"193","author":"Aksamit","year":"2016","journal-title":"American Thoracic Society 2016 International Conference"},{"issue":"Suppl 55","key":"10.1002\/14651858.CD012579.pub2-BIB0002|cit2","first-page":"1930","article-title":"Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis [Abstract]","volume":"38","author":"Alder","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14656566.2011.563735","article-title":"Inhaled gentamicin in non-cystic fibrosis bronchiectasis: Effects of long-term therapy","volume":"12","author":"Antoniu","year":"2011","journal-title":"Expert Opininion in Pharmacotherapy"},{"issue":"5","key":"10.1002\/14651858.CD012579.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD012579.pub2-BIB0006|cit6","first-page":"S494","article-title":"The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis","volume":"16","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0007|cit7","first-page":"A4536","article-title":"Baseline demographic profile of subjects from a study of inhaled aztreonam lysine for chronic gram negative infection with non-cystic fibrosis bronchiectasis","volume":"187","author":"Flume","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 55","key":"10.1002\/14651858.CD012579.pub2-BIB0008|cit8","first-page":"2534","article-title":"Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis","volume":"38","author":"Hampel","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD012579.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.160.5.9810080","article-title":"Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study","volume":"160","author":"Crowther Labiris","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/thorax.55.1.91a","article-title":"Nebulised taurolidine and B cepacia bronchiectasis","volume":"55","author":"Ledson","year":"2000","journal-title":"Thorax"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD012579.pub2-BIB0011|cit11","first-page":"S125","article-title":"Long-term nebulised gentamicin in non-cystic fibrosis bronchiectasis improves microbial load, exercise tolerance, exacerbation frequency and health-related quality of life","volume":"64","author":"Murray","year":"2009","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0012|cit12","unstructured":"NCT00749866 Long term nebulised gentamicin in patients with bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT00749866"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0013|cit13","unstructured":"NCT01313624 A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non-cf bronchiectasis - AIR-BX1 clinicaltrials.gov\/ct2\/show\/NCT01313624"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0014|cit14","unstructured":"NCT01677403 A study to access safety and efficacy of nebulized tobramycin in patients with bronchiectasis clinicaltrials.gov\/ct2\/show\/NCT01677403"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012579.pub2-BIB0015|cit15","first-page":"A68","article-title":"Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with pseudomonas aeruginosa","volume":"54","author":"O'Donnell","year":"1999","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0016|cit16","first-page":"A1775","article-title":"ORBIT-3 and ORBIT-4: design of a phase 3 program to investigate safety and efficacy of pulmaquin in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA)","volume":"193","author":"O'Donnell","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0954-6111(99)90090-2","article-title":"Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by pseudomonas aeruginosa","volume":"93","author":"Orriols","year":"1999","journal-title":"Respiratory Medicine"},{"issue":"Suppl","key":"10.1002\/14651858.CD012579.pub2-BIB0018|cit18","first-page":"42","article-title":"Effectiveness of inhaled antibiotic treatment for pseudomonas aeruginosa in outpatients with colonized bronchiectasis without mucoviscidosis","volume":"31","author":"Santiveri","year":"1995","journal-title":"Archivos de Bronconeumologia"},{"issue":"5","key":"10.1002\/14651858.CD012579.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"461; author rep","DOI":"10.1164\/ajrccm.186.5.461","article-title":"Randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis...without patient blinding","volume":"186","author":"Serisier","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0020|cit20","unstructured":"Shrewsbury SB Bilton D Gotfried M Jones SA The TABLE study (TOBI in acute bronchiectasis: additional treatment for exacerbations): rationale and methodology [Abstract] American Thoracic Society 100th International conference; 2004 May 21-26; Orlando 2004 A42 Poster A53"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD012579.pub2-BIB0021|cit21","first-page":"PA2617","article-title":"Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)","volume":"46","author":"Soyza","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"Suppl 56","key":"10.1002\/14651858.CD012579.pub2-BIB0022|cit22","first-page":"S215","article-title":"Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas","volume":"40","author":"Tabernero","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0023|cit23","first-page":"A1788","article-title":"Study design: effects of long term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis\u00a0 a double blind, randomized, placebo and TIS twice daily (open label) controlled trial. The BATTLE study","volume":"193","author":"Terpstra","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0024|cit24","unstructured":"Twiss J Byrnes CA Nebulized antibiotics reduce symptoms, bacterial density and oral antibiotic usage in children with non cystic fibrosis bronchiectasis American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008 A681"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012579.pub2-BIB0025|cit25","first-page":"A76","article-title":"Nebulised antibiotics reduce symptoms, bacterial density and oral antibiotic usage in children with non cystic fibrosis bronchiectasis","volume":"14","author":"J","year":"2009","journal-title":"Respirology"},{"issue":"Suppl 55","key":"10.1002\/14651858.CD012579.pub2-BIB0026|cit26","first-page":"S334","article-title":"Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis","volume":"38","author":"Wilson","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012579.pub2-BIB0027|cit27","first-page":"A135","article-title":"Quality of life effect of levofloxacin compared to ceftazidime treatment in infective exacerbation of bronchiectasis","volume":"9","author":"Wong","year":"2004","journal-title":"Respirology"},{"issue":"4","key":"10.1002\/14651858.CD012579.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","article-title":"Clinical phenotypes in adult patients with bronchiectasis","volume":"47","author":"Aliberti","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration","volume":"48","author":"Aliberti","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000320319","article-title":"Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms","volume":"81","author":"Altenburg","year":"2011","journal-title":"Respiration"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000320320","article-title":"Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy","volume":"81","author":"Altenburg","year":"2011b","journal-title":"Respiration"},{"issue":"12","key":"10.1002\/14651858.CD012579.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0033|cit33","unstructured":"Joint Formulary Committee British National Formulary www.medicinescomplete.com\/mc\/?utm_source=bnforg&utm_medium=homepage&utm_campaign=medicinescomplete"},{"issue":"2","key":"10.1002\/14651858.CD012579.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD012579.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"00081","DOI":"10.1183\/23120541.00081-2015","article-title":"The EMBARC European Bronchiectasis Registry: protocol for an international observational study","volume":"2","author":"Chalmers","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5694\/j.1326-5377.2002.tb04733.x","article-title":"Bronchiectasis in Indigenous children in remote Australian communities","volume":"177","author":"Chang","year":"2002","journal-title":"Medical Journal of Australia"},{"issue":"6","key":"10.1002\/14651858.CD012579.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/j.1326-5377.2010.tb03949.x","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation","volume":"193","author":"Chang","year":"2010","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0040|cit40","volume-title":"Antibiotic treatment for cystic fibrosis","author":"Cystic Fibrosis","year":"2009"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012733","article-title":"Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis","author":"Donovan","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012579.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.copbio.2008.11.002","article-title":"Aerosol antibiotics: considerations in pharmacological and clinical evaluation","volume":"19","author":"Dudley","year":"2008","journal-title":"Current Opinion in Biotechnology"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0043|cit43","article-title":"Bronchiectasis","volume-title":"European Lung White Book: Respiratory Health and Disease in Europe","author":"Gibson","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012514","article-title":"Dual antibiotics for non-cystic fibrosis bronchiectasis","author":"Felix Lambert","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012579.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"957-69","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012579.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respiratory Care"},{"issue":"1018","key":"10.1002\/14651858.CD012579.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/pgmj.2009.091041","article-title":"Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century","volume":"86","author":"Goeminne","year":"2010","journal-title":"Postgraduate Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD012579.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/resp.12219","article-title":"The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis","volume":"19","author":"Goeminne","year":"2014","journal-title":"Respirology"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1183\/13993003.01567-2015","article-title":"Bronchiectasis: how to be an orphan with many parents?","volume":"47","author":"Pieter","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0050|cit50","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/1817-1737.82443","article-title":"Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis","volume":"6","author":"Habesoglu","year":"2011","journal-title":"Annals of Thoracic Medicine"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0052|cit52","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD012579.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"pii: 1700051","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"Hill","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"8","key":"10.1002\/14651858.CD012579.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001392.pub3","article-title":"Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults","author":"Hnin","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012590","article-title":"Head-to-head trials of antibiotics for non-cystic fibrosis bronchiectasis","author":"Kaehne","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012579.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012406","article-title":"Macrolide antibiotics for non-cystic fibrosis bronchiectasis","author":"Kelly","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012579.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1440-1843.1996.tb00037.x","article-title":"Bronchiectasis: a neglected cause of respiratory morbidity and mortality","volume":"1","author":"Kolbe","year":"1996","journal-title":"Respirology"},{"issue":"12","key":"10.1002\/14651858.CD012579.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","article-title":"Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity","volume":"12","author":"Lonni","year":"2015","journal-title":"Annals of the American Thoracic Society"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65 Suppl 1","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"pii: 1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"issue":"6","key":"10.1002\/14651858.CD012579.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"762-1; discussi","DOI":"10.4187\/respcare.04208","article-title":"Aerolized antibiotics","volume":"60","author":"Restrepo","year":"2015","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0065|cit65","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.rmed.2010.02.022","article-title":"Trends in bronchiectasis mortality in England and Wales","volume":"104","author":"Roberts","year":"2010","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012579.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2007.0652","article-title":"Aerosolized antibiotics for noncystic fibrosis bronchiectasis","volume":"21","author":"Rubin","year":"2008","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001021.pub2","article-title":"Inhaled antibiotics for long-term therapy in cystic fibrosis","author":"Ryan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1378\/chest.10-0099","article-title":"Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006","volume":"138","author":"Seitz","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012579.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1378\/chest.11-2209","article-title":"Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007","volume":"142","author":"Seitz","year":"2012","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD012579.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomised controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD012579.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/(SICI)1099-0496(200003)29:3<182::AID-PPUL5>3.0.CO;2-T","article-title":"Bronchiectasis in Alaska Native children: causes and clinical courses","volume":"29","author":"Singleton","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD012579.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002203.pub4","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012579.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010337.pub2","article-title":"Interventions for bronchiectasis: an overview of Cochrane systematic reviews","author":"Welsh","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012579.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clinical Pulmonary Medicine"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rmed.2016.06.007","article-title":"Challenges in managing pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis","volume":"117","author":"Wilson","journal-title":"Respiratory Medicine"},{"issue":"9842","key":"10.1002\/14651858.CD012579.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012579.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Yang JW Fan LC Lu HW Miao XY Mao B Xu JF Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis Clinical Respiratory Journal 2016 731 9 10.1111\/crj.12278","DOI":"10.1111\/crj.12278"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012579.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T11:28:26Z","timestamp":1653218906000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012579.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012579.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]}}}